Carfilzomib consolidation with cyclophosphamide and dexamethasone conferred noninferior results compared to upfront autologous stem cell transplantation in newly diagnosed, transplant-eligible patients with multiple myeloma.
Recent Content
- Genetic test aims to simplify care for certain blood cancer patients
- Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy
- The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review
- Anti-CD38-based quadruplet versus triplet induction regimens in transplant-ineligible newly diagnosed multiple myeloma: a systematic review and meta-analysis
- (no title)
- Electrical therapy shows promise for metastatic pancreatic cancer
- Outcomes of hematopoietic stem cell transplantation in patients aged 70 years and older
- Glioblastoma treatment GLIX1 enters human trials
- Groundbreaking Results Shift Treatment Paradigm in High-Risk Smoldering Multiple Myeloma
- Prophylactic Immunoglobulin Supplementation for Infection Prevention in Multiple Myeloma: An Updated Systematic Review and Meta-Analysis